Robert Weixeldorfer, OD
Optometrist · Lees Summit, MONPI 1528051802
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,615 of the $13,529 with a category attached, or 85.9%. 17 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 41.6% of the total. Reporting peaked in 2019 at $4,490 and has fallen 74.3% since, to $1,156 in 2025. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $59.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$6K
- Bausch & Lomb Americas Inc.$4K
- Alcon$1K
- Biotissue Holdings Inc.$569
- Coopervision Inc.$497
- AbbVie$399
- plus $1K from 11 others
What the payments were for
- Travel & lodging$1,91414%
- Food & beverage$11,61586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 68 | $5,631 |
| Bausch & Lomb Americas Inc. | 70 | $4,019 |
| Alcon | 24 | $1,128 |
| Biotissue Holdings Inc. | 12 | $569 |
| Coopervision Inc. | 17 | $497 |
| AbbVie(2 entities) | 10 | $399 |
| Aerie Pharmaceuticals, Inc. | 2 | $244 |
| Sight Sciences, Inc. | 3 | $189 |
| Novartis | 4 | $184 |
| Johnson & Johnson Vision Care, Inc. | 7 | $182 |
| Amgen | 1 | $118 |
| Synergeyes, Inc. | 1 | $84 |
| Ocular Therapeutix, Inc. | 1 | $81 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Oyster Point Pharma, Inc. | 1 | $64 |
| Thea Pharma Inc. | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTRA$2,348
- BIOTRUE$1,880
- INFUSE$1,688
- BIOTRUE ONE DAY$1,226
- BTOD$837
- TOTAL30$245
- Rhopressa$244
- Rocklatan$244
- ULTRA MULTIFOCAL TORIC$243
- RESTASIS$241
- OMNI(R) SURGICAL SYSTEM (US)$148
- XIIDRA$120
- MIEBO$119
- VYZULTA$119
- TEPEZZA$118
- Multiple Brands Contact Lens$111
- Hydrus Microstent$111
- Precision 1$109
- Prokera$106
- AmnioGraft$106
How this compares
$13,529 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 130 | $50,465 |
| RestasisCyclosporine | 34 | $34,398 |
| Cyclosporine | 27 | $20,738 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $8,363 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $3,207 |
| Latanoprost | 392 | $3,063 |
| Brimonidine Tartrate | 31 | $1,805 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $709 |
| Prednisolone Acetate | 23 | $677 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 29 | $321 |
| ErythromycinErythromycin Base | 20 | $284 |
| Timolol Maleate | 37 | $283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $399 | $93,226190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Lees Summit
- Mark HerriottLees Summit$14K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
- Ariel CerenzieSaint Louis$76K
- Geoffrey PowellKansas City$55K
- Thomas HobbsSedalia$53K
- Heather WebsterColumbia$52K
- Sean MulqueenyCreve Coeur$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.